Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients

Phase 4

Terminated

• Conditions: Glycogen Synthase Kinase 3
• Interventions: Drug: Sevoflurane; Drug: Propofol

• Registration Number: NCT02686710
• Lead Sponsor: Moscow Regional Research and Clinical Institute (MONIKI)

Brief Summary

Assessment of GSK-3beta contents in leukocytes in on-pump cardiosurgical patients receiving either volatile or intravenous anesthesia

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02
• Study First Submitted: 2016-02-16
• Study First Submitted QC: 2016-02-16
• Study First Posted: 2016-02-19
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-13
• Last Update Posted: 2019-08-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

elective on-pump CABG

Exclusion Criteria

re-operation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VIMA	Sevoflurane	Patiens receiving volatile induction and maitenance of anesthesia
TIVA	Propofol	Patiens receiving total intravenous anesthesia based on propofol
Combi	Sevoflurane	Patiens receiving total intravenous induction and volatile anesthesia
Combi	Propofol	Patiens receiving total intravenous induction and volatile anesthesia

Primary Outcome Measures

Name	Time	Method
Gsk-3beta base line content	base line
Gsk-3beta content after induction	20 minutes after tracheal intubation
Gsk-3beta content after surgery	immediately after surgery

Trial Locations

Locations (1)

Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy; 🇷🇺 Moscow, Russian Federation